# Determining the Prognostic Value of Continuous Intrathecal Infusion

> **NCT03523000** · PHASE4 · COMPLETED · sponsor: **University Hospitals Cleveland Medical Center** · enrollment: 36 (actual)

## Conditions studied

- Lumbar Post-Laminectomy Syndrome
- Chronic Low Back Pain
- Vertebral Compression Fracture
- Failed Back Surgery Syndrome

## Interventions

- **OTHER:** Continuous intrathecal prognostic infusion test
- **DRUG:** Bupivacaine
- **DRUG:** Fentanyl
- **DRUG:** Placebo
- **DEVICE:** Intrathecal Drug Delivery System (IDDS)

## Key facts

- **NCT ID:** NCT03523000
- **Lead sponsor:** University Hospitals Cleveland Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-18
- **Primary completion:** 2021-10-12
- **Final completion:** 2021-10-12
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03523000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03523000, "Determining the Prognostic Value of Continuous Intrathecal Infusion". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT03523000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*